Amylin-GLP-1 research studies dual-receptor peptide activity, pairing an amylin analog with a GLP-1 analog to observe combined effects on satiety signaling, gastric emptying, and glucose-dependent insulin secretion in lab models. Researchers need lot-matched peptides with verified purity (98% or higher by HPLC is the stated baseline) and aggregate screening, because amylin analogs aggregate more readily than GLP-1 analogs.
Key points
- Amylin GLP-1 research in 2026 centers on dual agonists like cagrilintide-semaglutide and amycretin, both studied for combined satiety and glucose effects.
- Matched-lot sourcing of the amylin and GLP-1 components matters more than raw peptide count for reproducible data.
- Peptide purity at or above 98% by HPLC is the baseline researchers expect before running co-administration protocols.
- GLP-123 supplies amylin and GLP-1 analog research peptides with certificates of analysis for labs building dual-receptor protocols.
Amylin GLP-1 research is the study of dual-receptor peptide activity, pairing an amylin analog with a GLP-1 analog to observe combined effects on satiety signaling, gastric emptying, and glucose-dependent insulin secretion in lab models. Researchers working this space need peptides with verified purity, matched-lot documentation, and reconstitution protocols that don't introduce variability between the amylin and GLP-1 components. That's a different bar than single-agonist GLP-1 work, because two molecules with different aggregation and stability profiles now have to behave consistently in the same protocol.
CAGRISEMA (cagrilintide, an amylin analog, combined with semaglutide) is the reference example most labs cite when discussing amylin-GLP-1 co-agonism, and it sets the template for how researchers structure dual-receptor study designs in 2026.
- Amylin GLP-1 research in 2026 centers on dual agonists like cagrilintide-semaglutide and amycretin, both studied for combined satiety and glucose effects.
- Matched-lot sourcing of the amylin and GLP-1 components matters more than raw peptide count for reproducible data.
- Peptide purity at or above 98% by HPLC is the baseline researchers expect before running co-administration protocols.
- GLP-123 supplies amylin and GLP-1 analog research peptides with certificates of analysis for labs building dual-receptor protocols.
Why amylin-GLP-1 research matters for metabolic disease researchers
Single-target GLP-1 receptor work has been documented for years. What's changed by 2026 is the volume of published interest in stacking amylin's satiety and gastric-emptying effects on top of GLP-1's insulinotropic and appetite-signaling effects, since the two hormones act on distinct receptor systems that appear to produce additive effects in preclinical models.
That's why dual agonists like amycretin, which combines amylin receptor and GLP-1 receptor activity in one molecule, and cagrilintide-semaglutide combinations show up repeatedly in current metabolic research literature. For a research team, this shifts the sourcing problem: you're no longer managing one peptide's stability profile, you're managing two, sometimes three if you're layering in a coformulation variable.
Amylin analogs also carry a distinct handling risk that GLP-1 analogs largely don't: a stronger tendency toward aggregation and fibril formation during storage and reconstitution. A researcher who treats an amylin peptide like a standard GLP-1 vial is set up for inconsistent results before the study even starts.
Building an amylin-GLP-1 research protocol, step by step
Define the receptor interaction you're actually testing
Before sourcing anything, pin down whether the protocol is testing co-administration (two separate peptides, same model, same timeline) or a fixed coformulation (one vial, one ratio, no mixing step). This decision changes every downstream choice.
- Co-administration: independent dosing schedules, independent stability tracking
- Fixed-ratio coformulation: single reconstitution event, single degradation curve
- Sequential dosing: staggered administration to separate receptor activation windows
- Dose-ranging: multiple ratios of amylin analog to GLP-1 analog across cohorts
Source amylin and GLP-1 analog peptides from documented lots
Matching lot numbers, or at minimum matching certificate-of-analysis dates, keeps variability between the amylin component and the GLP-1 component from confounding your results. Sourcing two peptides from two different vendors with two different QC standards is the single fastest way to introduce noise into dual-agonist data.
- Request a certificate of analysis for every lot before use
- Confirm purity by HPLC, ideally 98% or higher
- Match reconstitution dates across the amylin and GLP-1 components
- Track mass spec identity confirmation, not just purity percentage
- Log storage temperature history from receipt to use
Verify purity and identity before any dosing begins
Amylin analogs are more prone to aggregation than most GLP-1 peptides, which means a purity number alone doesn't tell you the whole story — aggregate content matters as much as the headline purity figure. Purity testing protocols built for GLP-1 peptides generally extend to amylin analogs with the same HPLC and mass spec workflow, but researchers should confirm the assay covers aggregate detection specifically.
- HPLC purity assay with a documented reference standard
- LC-MS identity confirmation matching expected molecular weight
- Aggregate/oligomer screening, not just monomer purity
- Endotoxin testing if the model involves any in vivo component
Reconstitute with a protocol that controls for shear and temperature
Amylin analogs are more sensitive to mechanical stress during reconstitution than most GLP-1 peptides. Aggressive shaking or rapid injection of bacteriostatic water into a lyophilized amylin vial increases fibril formation risk and skews your baseline before the study starts.
- Add diluent slowly, along the vial wall, not directly onto the cake
- Swirl gently rather than shaking
- Reconstitute at room temperature, then return to cold storage immediately
- Use a fresh syringe and needle per vial to avoid cross-contamination
- Document reconstitution time and temperature in the study log
Establish a stability and degradation baseline for both components
Run a short stability check on the amylin peptide and the GLP-1 peptide independently before combining them in a co-administration design. If one degrades faster than the other under your storage conditions, that mismatch will show up as noise in week three or four of a longer protocol, not week one.
- Pull time-point samples at day 0, 7, 14, and 28
- Track both peptides under identical storage conditions
- Flag any visible turbidity or precipitate immediately
- Compare degradation curves against the certificate of analysis baseline
Document every batch with a certificate of analysis
A study built on two peptides needs two certificates of analysis on file, not one. This is the fastest way to catch a supplier substitution or a lot change that would otherwise go unnoticed until data stops replicating.
Sourcing amylin and GLP-1 analog peptides from a single supplier with consistent lot documentation removes one variable from this whole process. GLP-123 lists certificates of analysis alongside each amylin and GLP-1 research peptide, which shortens the verification step described above without skipping it.
Structure the co-administration or coformulation timeline
Once sourcing and QC are locked, the actual dosing schedule needs to reflect whether you're testing simultaneous receptor activation or a staggered effect. Coformulation research protocols differ from co-administration protocols specifically in how the ratio between the amylin and GLP-1 components is held constant across the study.
- Fixed-ratio designs need a single reconstitution event per cohort
- Staggered designs need independent timing logs for each peptide
- Cross-over designs need a washout period documented in the protocol
Comparing sourcing options for amylin-GLP-1 research
| Option | Best for | Key limitation |
|---|---|---|
| Separately sourced amylin analog + GLP-1 analog | Co-administration studies with independent dosing control | Requires matching QC standards across two vendors |
| Pre-combined dual-agonist peptide (e.g., cagrilintide-semaglutide type) | Fixed-ratio coformulation studies | Ratio is locked; no mid-study adjustment |
| In-house custom coformulation | Labs testing novel amylin-GLP-1 ratios | Requires internal QC capacity to validate stability |
Verdict: separately sourced, lot-matched amylin and GLP-1 analog peptides give the most control for co-administration protocols; pre-combined peptides work better when the study design calls for a fixed ratio and simplified logistics.
“If the amylin analog and the GLP-1 analog aren’t tested from documented, dated lots, the co-administration data isn’t reproducible.”
Common mistakes in amylin-GLP-1 research
- Treating amylin like a standard GLP-1 peptide during reconstitution. Amylin analogs aggregate faster under mechanical stress, so a reconstitution method that works fine for a GLP-1 peptide can degrade an amylin component.
- Sourcing the two peptides from mismatched lots or vendors. Independent QC standards between the amylin and GLP-1 components introduce variability that gets misread as a biological effect.
- Skipping aggregate screening on the amylin analog. A high monomer purity number can still mask meaningful oligomer content that changes receptor binding behavior.
- Assuming coformulation and co-administration protocols are interchangeable. A fixed-ratio coformulation study can't be substituted mid-protocol with independently timed dosing without changing what the data actually measures.
- Under-documenting storage temperature history. Amylin peptides that see even brief warming during shipping or handling show up as inconsistent baselines weeks later.
FAQ
What is amylin GLP-1 research?
Amylin GLP-1 research studies the combined effects of an amylin receptor agonist and a GLP-1 receptor agonist in the same protocol, often to observe additive effects on satiety signaling and glucose-dependent insulin secretion. Cagrilintide-semaglutide combinations and amycretin are the most commonly cited dual-agonist examples in 2026 research.
Is cagrilintide the same as amylin?
Cagrilintide is a long-acting amylin analog, not naturally occurring amylin itself. It’s engineered for extended activity at the amylin receptor and is most often studied in combination with semaglutide, a GLP-1 analog.
How do researchers combine amylin and GLP-1 analogs in a study?
Researchers either co-administer two separately sourced peptides on independent dosing schedules or use a fixed-ratio coformulation reconstituted as a single vial. The choice depends on whether the protocol needs independent control over each component’s dosing.
What’s the difference between coformulation and co-administration?
Coformulation combines both peptides into one fixed ratio reconstituted together, while co-administration keeps the amylin and GLP-1 components separate with independent timing. Coformulation simplifies logistics but locks the ratio for the full study.
How stable are amylin peptides during storage compared to GLP-1 peptides?
Amylin analogs generally show a higher tendency toward aggregation and fibril formation than most GLP-1 peptides, making storage temperature and reconstitution handling more critical. A stability check at day 0, 7, 14, and 28 catches degradation before it affects study data.
Does amycretin count as amylin-GLP-1 research?
Yes. Amycretin is designed as a single molecule with activity at both the amylin and GLP-1 receptors, making it a dual-agonist candidate rather than a two-peptide combination like cagrilintide-semaglutide.
What purity level should amylin-GLP-1 research peptides meet?
Most labs expect HPLC purity at or above 98%, paired with LC-MS identity confirmation and aggregate screening specific to the amylin component. Purity percentage alone doesn’t rule out oligomer content that can affect receptor binding.
Where can labs source amylin and GLP-1 research peptides in 2026?
Labs should source from suppliers that provide a certificate of analysis per lot, covering purity, identity, and endotoxin data. GLP-123 lists this documentation alongside its amylin and GLP-1 analog research peptides.
One last thing
The detail most researchers miss isn't purity, it's aggregation. Two peptides can each test at 98% purity independently and still produce inconsistent co-administration data if the amylin component picked up oligomer content during shipping or reconstitution that a standard HPLC purity assay doesn't flag on its own. Screen for aggregates specifically, not just monomer purity, before drawing conclusions from any amylin-GLP-1 protocol run in 2026.
Related guides
Originally published on glp-123.com. This library mirrors the guide for easier reading. Products mentioned are for laboratory research only.
View original



